Up 10%: Why the Polynovo share price is popping today

Polynovo shares are rocketing for the second day in a row…

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's looking like another strong day for ASX shares and the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday. At the time of writing, the ASX 200 has gained a healthy 0.38%, putting the index back over 7,500 points. But let's discuss the Polynovo Ltd (ASX: PNV) share price.

Polynovo shares are putting the gains of the broader market to shame so far this Tuesday. At present, the ASX 200 healthcare stock is up a whopping 8.16% at $1.88 a share. That's after Polynovo stock lifted as high as $1.92 soon after market open this morning (up more than 10% at the time).

So what's going on with this healthcare company today that is resulting in these kinds of stellar share price moves?

Polynovo shares spike 10% on bumper trading result

It seems that these gains can be put down to the trading update Polynovo released yesterday during trading hours.

As we briefly touched on yesterday afternoon, this indicative trading update (covering the first half of FY2024) was probably responsible for Polynovo shares' near-10% rise for Monday's session.

It's not too hard to see why.

Polynovo told investors that its total global revenue for the first half of FY2024 came in at 48.8 million, up 65.6% from the $29.5 million recorded at this time last year.

The company also achieved a record sales revenue of $42.2 million (up 54.9%), as well as U.S. sales of $32.2 million (up 41.7%).

Rest of world sales rocketed 122.2% to $10 million.

The company also reported positive earnings before interest, tax, depreciation and amortisation (EBITDA), and a net profit after tax (NPAT) for the period. Excluding non-cash items, Polynovo achieved an underlying EBITS of $3.6 million for the period.

Polynovo chair David Williams had this to say on these numbers:

While I view profit as a 'nice to have', I am more excited by the significant near-term revenue growth possibilities from our expanding geographic footprint and the new ways surgeons have found to use our products. Profits will drop naturally out of the drive and success in expanding our geographies and products.

Given most of yesterday's strong share price gains came after Polynovo released this update, it seems that we can thank it for both those gains, and the further rise we are seeing today.

But despite these gains, the Polynovo share price remains down by 25.8% over the past 12 months.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »